Zepbound in Canada: weight management and sleep apnea

Zepbound at a glance

A prescription tirzepatide product authorized for chronic weight management in adults who meet its criteria and for moderate-to-severe obstructive sleep apnea in adults with obesity.^[1]

Zepbound’s sleep-apnea use is a defined medical indication

Zepbound and Mounjaro contain tirzepatide, but Mounjaro is the type 2 diabetes product. Read the ingredient-level guide without treating the brands as interchangeable.

The sleep-apnea indication is a product-specific medical use, not a general claim that weight change alone treats every sleep disorder. Diagnosis, suitability and follow-up require qualified care.^[1][2][3]

Assessment depends on the indication being considered

A useful assessment identifies the actual treatment question, checks the applicable monograph criteria and reviews conditions, medicines, contraindications, goals and follow-up. An online brand request cannot perform that work.

Sleep-apnea care requires its own diagnostic and follow-up pathway

The product-specific obstructive-sleep-apnea indication does not mean that every sleep concern or every person with obesity fits that use. Diagnosis, severity and follow-up remain clinical questions.

The cited 10 mg/0.6 mL multi-dose pen record, DIN 02557533, is Marketed when checked August 14, 2026. Other strengths are separate DINs; verify the prescribed presentation, and do not translate DPD lifecycle into local stock.

If prescribed, use that presentation for the pharmacy-price check and ask the payer which indication and DIN its rule covers.^[1][2][3][4]